The Funagata study conducted on a Japanese cohort revealed that IGT is a risk factor for CVDs and stroke [7]
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
Reconstituted with 1mL for 20mg/mL concentration, even the highest 12mg dose only requires 60 units, well within a single syringe draw
Tirzepatide has already been approved by the FDA for the management of chronic weight in adults who are either obese or overweight and have at least one condition related to weight
Semaglutide works by mimicking the GLP-1 hormone to regulate blood sugar and reduce appetite, while retatrutide mimics three hormonesGLP-1, GIP, and GCG to potentially offer more comprehensive benefits for weight loss, blood sugar control, and metabolism
This is more than with earlier GLP-1 medications